Rockefeller Capital Management L.P. Acquires 5,000 Shares of Aurinia Pharmaceuticals Inc $AUPH

Rockefeller Capital Management L.P. grew its holdings in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 6.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 84,165 shares of the biotechnology company’s stock after acquiring an additional 5,000 shares during the quarter. Rockefeller Capital Management L.P. owned 0.06% of Aurinia Pharmaceuticals worth $713,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. MAI Capital Management bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at approximately $39,000. Kazazian Asset Management LLC bought a new position in Aurinia Pharmaceuticals in the 1st quarter valued at approximately $84,000. Mackenzie Financial Corp acquired a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $86,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth $92,000. Finally, Cerity Partners LLC acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter worth $96,000. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Up 0.6%

Shares of AUPH stock opened at $16.37 on Thursday. Aurinia Pharmaceuticals Inc has a 1-year low of $6.55 and a 1-year high of $16.48. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of 38.07 and a beta of 1.30. The stock has a 50-day moving average of $13.11 and a 200-day moving average of $10.86.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07. The company had revenue of $73.47 million for the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Royal Bank Of Canada reissued a “sector perform” rating and set a $15.00 price objective (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Bloom Burton cut Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a report on Wednesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Finally, Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the stock from $10.00 to $21.00 in a research report on Friday, November 7th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $17.67.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.